Artemisinin-based combination therapy (ACT) reduces the potential for malaria transmission compared with non-ACTs. It is unclear whether this effect differs between ACTs. Methods. A total of 298 children (age, 6 months to 10 years) with uncomplicated falciparum malaria were ran-domized to artemether-lumefantrine (AL; n = 153) or dihydroartemisinin-piperaquine (DP; n = 145) in Mbita, a community in western Kenya. Gametocyte carriage was determined by molecular methods on days 0, 1, 2, 3, 7, 14, 28, and 42 after treatment initiation. The gametocyte infectiousness to mosquitoes was determined by mosquito-feeding assays on day 7 after beginning therapy. Results. The cumulative risk of recurrent parasitemia on day 42 after initiation of treatment, unadjusted by polymerase chain reaction findings, was 20.7% (95% confidence interval [CI], 14.4–28.2) for AL, compared with 3.7% (95% CI, 1.2–8.5) for DP (P < .001). The mean duration of gametocyte carriage was 5.5 days (95% CI, 3.6–8.5) for AL and 15.3 days (95% CI, 9.7–24.2) for DP (P = .001). The proportion of mosquitoes that became infected after feeding on blood from AL-treated children was 1.88% (43 of 2293), compared with 3.50% (83 of 2371) for those that fed on blood from DP-treated children (P = .06); the oocyst burden among mosquitoes was lower among those that fed on blood from AL-treated children (P = .005) Conclusions. While DP was associated with a longer prophylactic time after treatment, gametocyte carriage and malaria transmission to mosquitoes was lower after AL treatment.